Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Corporate Governance

The Hansa Biopharma corporate governance model is set forth in the diagram below. It illustrates the central corporate bodies during 2021. Details on the significant external and internal regulations and policies that affect corporate governance, is specified in our Annual Report 2020.

Our Governance Structure

Governance Committees

Audit Committee

After the 2021 AGM, the Audit Committee consisted of Eva Nilsagård (CHAIRMAN), Mats Blom, and Andreas Eggert. The committee is obligated to keep minutes of its meetings and make the minutes available to the Board. The Audit Committee shall perform the duties incumbent upon audit committees as required by law and the Swedish Code of Corporate Governance.

The primary duties of the audit committee are to:

  • monitor the Company’s financial reporting;
  • with respect to the financial reporting, monitor the effectiveness of the Company’s internal controls, internal audit and risk management;
  • inform itself of the audit of the annual reports and group accounts;
  • review and monitor the auditor’s impartiality and independence, and, in this context, particularly monitor whether the auditor is providing the Company with services other than auditing services;
  • take decisions regarding guidelines for services other than the auditing services which the external auditor can provide.

Nomination Committee

Hansa Biopharma’s nomination committee comprises Natalie Berner (representing Redmile Group), Thomas Olausson, Jannis Kitsakis (representing AP4). The nomination committee prepares a proposal regarding the number of directors and persons to be elected as directors, including the chairman, and a proposal for remuneration to the chairman and the other board members, as well as a proposal for remuneration for the board members’ committee work. The nominatio n committee also proposes election of auditors including remuneration to the auditor.

The Nomination Committee shall consist of representatives for the three largest, in terms of votes, registered shareholders per August 31, 2021. The names of the members of the Nomination Committee will be made public no later than six months prior to the Annual General Meeting of 2022.

Principles for appointing the Nomination Committee

Scientific Committee

After the 2021 AGM, the Scientific Committee consists of Anders Gersel Pedersen (CHAIRMAN), Andreas Eggert, Ulf Wiinberg, and Hilary Malone. The committee is obligated to keep minutes of its meetings and make the minutes available to the Board.

The primary duties of the scientific committee are to:

  • assist the Board with recommendations regarding the Company’s research and development strategies and possibilities;
  • perform such other duties as are considered necessary and appropriate in conjunction with the work set forth above; and perform such other duties as instructed by the Board from time to time.

Remuneration Committee

After the 2021 AGM, the remuneration committee has consisted of Andreas Eggert (CHAIRMAN), Ulf Wiinberg and Anders Gersel Pedersen. The remuneration committee is charged with performing the duties set forth in the Swedish Corporate Governance Code. The committee is obligated to keep minutes of its meetings and make the minutes available to the Board.

The primary duties of the remuneration committee are to:

  • prepare decisions for the Board regarding remuneration principles, remuneration and other employment terms and conditions for senior management, among other things by proposing to the Board, if applicable, the guidelines for remuneration to senior management, to be adopted at the AGM of the shareholders;
  • monitor and evaluate any programs pending or adopted during the year for variable compensation for senior management;
  • monitor and evaluate the application of the guidelines for remuneration adopted by the AGM, as well as applicable remuneration structures and levels for the Company.

Guidelines for executive remuneration

Meetings

General Meeting

2021

Annual General Meeting 2021 in Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, Sweden, will hold its Annual General Meeting on Wednesday May 12, 2021.

Information about the Annual General Meeting and the forms for its implementation will be provided in the notice convening the Annual General Meeting. Shareholders wishing to submit proposals ahead of the Annual General Meeting may do so at least seven weeks before the Annual General Meeting, via e-mail to ir@hansabiopharma.com or by letter to Hansa Biopharma, Box 785, SE-220 07 Lund, Sweden.

Notice to the Annual General Meeting 2021

Notification of attendance and form for advance voting

The Nomination Committee of Hansa Biopharma AB (publ)’s explanatory statement to the Annual General Meeting 2021

Proxy form

The Board of Directors’ statement under Chapter 19, Section 22 of the Swedish Companies Act

The Board of Directors’ proposal regarding guidelines for executive remuneration

Auditor’s opinion under Chapter 8 Section 54 of the Swedish Companies Act (2005:551) as to whether the guidelines of the annual general meeting on the remuneration of senior executives have been followed

Remuneration Report 2020

2020

Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, summons to Annual General Meeting on Tuesday June 23, 2020 at 15:00 CEST at the Elite Hotel Ideon, Scheelevägen 27, SE-223 63 Lund, Sweden. Registration will begin at 14:00 CEST and will end when the meeting starts.

Right to attend the Annual General Meeting

To have the right to participate in the Annual General Meeting, the shareholder must be included in the shareholders’ register kept by Euroclear Sweden AB as of June 16, 2020 and notify the company of his or her participation at the Annual General Meeting no later than June 16, 2020. Notice to participate shall be given in writing to Advokatfirman Vinge KB, Att: Stephanie Stiernstedt, Box 1703, 111 87 Stockholm or by e-mail to hansabiopharma@vinge.se. The notification shall state the shareholder’s name, personal identity number or registration number, telephone number and, where applicable, the number of advisors (maximum two).

A shareholder, whose shares have been registered in the name of a bank or other trust department or with a private securities broker, must temporarily re-register his or her shares in his or her own name with Euroclear Sweden AB to be entitled to participate in the Annual General Meeting. Such re-registration must be completed no later than June 16, 2020 and should be requested with the nominee well in advance.

The Board of Directors' proposal for new articles of association

The Board of Directors’ proposal to adopt a long-term incentive program based on employee stock options for employees at Hansa Biopharma

The Board of Directors’ proposal to adopt a long-term incentive program based on performance-based share rights for employees at Hansa Biopharma

The Board of Directors’ statement under Chapter 19, Section 22 of the Swedish Companies Act

The Nomination Committee of Hansa Biopharma AB (publ)’s explanatory statement to the Annual General Meeting 2020

Auditor’s opinion under Chapter 8 Section 54 of the Swedish Companies Act (2005:551) as to whether the guidelines of the annual general meeting on the remuneration of senior executives have been followed

Notification of attendance and form for advance voting

Proxy form

Report by the Board of Directors of Hansa Biopharma AB (publ), on the Remuneration Committee’s evaluation of compensation to the Executive Management

The Board of Director’s proposal for executive remuneration

Notice (press release)

Minutes from the AGM

2019

Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, summons to Annual General Meeting on Wednesday 22 Maj 2019 at 17.00 CEST at the auditorium next to the Company’s premises, Scheelevägen 22, Lund, Sweden. Registration will begin at 16.30 CEST and will end when the meeting starts.

Right to attend the Annual General Meeting

To have the right to participate in the Annual General Meeting, the shareholder must be included in the shareholders’ register kept by Euroclear Sweden AB as of 16 May 2019 and notify the company of his or her participation at the Annual General Meeting no later than 16 May 2019. Notice to participate shall be given in writing to Hansa Biopharma AB (publ), Box 785, 220 07 Lund or by e-mail to agm@hansabiopharma.com. The notification shall state the shareholder’s name, personal identity number or registration number, daytime telephone number and, where applicable, the number of advisors (maximum two).

A shareholder, whose shares have been registered in the name of a bank or other trust department or with a private securities broker, must temporarily re-register his or her shares in his or her own name with Euroclear Sweden AB to be entitled to participate in the Annual General Meeting. Such re-registration must have been completed no later than 16 May 2019 and should be requested with the nominee well in advance.

Read the full notice to Annual General Meeting

The Nomination Committee of Hansa Biopharma AB (publ) explanatory statement to the Annual General Meeting 2019

Shareholders proxy form AGM 2019

Hansa Biopharma AB (publ) Annual Report 2018

The Board of Directors’ proposal to adopt a long term incentive programme based on warrants and employee stock options for employees in Hansa Biopharma

The Board of Directors’ proposal to adopt a long term incentive programme based on performance based share rights for employees in Hansa Biopharma

The board of directors’ statement under Chapter 19, Section 22 of the Swedish Companies Act

Terms and Conditions for the Option Programme 2019 in Hansa Biopharma AB (publ) in Series 1

Terms and Conditions for the Option Programme 2019 in Hansa Biopharma AB (publ) in Series 2

Report by the Board of Directors of Hansa Biopharma AB (publ), on the Remuneration Committee’s evaluation of compensation to the Executive Management

Auditor’s opinion under Chapter 8 Section 54 of the Swedish Companies Act (2005:551) as to whether the guidelines of the annual general meeting on the remuneration of senior executives have been followed

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) 2019

Minutes from the Annual General Meeting 2019

2018

Notice of Annual General Meeting of Hansa Medical AB (publ)

Hansa Medical AB (publ) summons to Annual General Meeting on May 29, 2018 at 17.00 CEST at the auditorium next to the Company’s premises, Scheelevägen 22, Lund, Sweden.

The shareholders of Hansa Medical AB (publ) are hereby summoned to the Annual General Meeting on May 29, 2018, at 17.00 CEST at the auditorium next to the Company’s premises, Scheelevägen 22, Lund, Sweden. Registration will begin at 16.30 CEST and will end when the meeting starts.

Right to attend the Annual General Meeting

To have the right to participate in the Annual General Meeting, the shareholder must be included in the shareholders’ register kept by Euroclear Sweden AB as of May 23, 2018, and notify the company of his or her participation at the Annual General Meeting no later than May 23, 2018. Notice to participate shall be given in writing to Hansa Medical AB, Hansa Medical AB (publ), Box 785, 220 07 Lund or by e-mail to hansamedical@vinge.se. The notification shall state the shareholder’s name, personal identity number or registration number, daytime telephone number and, where applicable, the number of advisors (maximum two).

A shareholder, whose shares have been registered in the name of a bank or other trust department or with a private securities broker, must temporarily re-register his or her shares in his or her own name with Euroclear Sweden AB to be entitled to participate in the Annual General Meeting. Such re- registration must have been completed no later than May 23, 2018 and should be requested with the nominee well in advance.

Read the full notice to Annual General Meeting

Auditors opinon

Hansa Medicals Annual report 2017

Remuneration committees evaluation of compensation to Senior Management

Shareholders proxy form AGM 2018

The board of directors’ statement under Chapter 19

The nomination committees explanatory statement to the Annual General Meeting 2018

The Board of Directors’ proposal to adopt a long term incentive programme

Terms and Conditions for Warrants 2018

2017

The shareholders of Hansa Medical AB (publ) are hereby summoned to attend the Annual General Meeting (“AGM”) on May 23rd, 2017, at 17.00 CET at the auditorium next to the Company’s premises, Scheelevägen 22, Lund, Sweden. Registration starts at 16.30 CET and will stop when the meeting starts.

Right to attend the Annual General Meeting

Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per May 17th, 2017, and who, no later than May 17th, 2017 at 12.00 CET, give notice to the company of their intent to participate at the AGM have a right to participate in the AGM. Notice to participate shall be given in writing to Hansa Medical AB, c/o Fredersen Advokatbyrå AB, Turning Torso, 211 15 Malmö, by e-mail to hansamedical@fredersen.se or by fax to +46-40-232003. The notice shall contain the shareholder’s name, personal identity number or registration number and daytime telephone number and, where applicable, the number of advisors (maximum two). After giving notice of participation the shareholder will receive a confirmation. If no confirmation is received, notice has not been duly given.

A shareholder whose shares are registered under the name of a nominee must temporarily register his shares in his own name with Euroclear Sweden AB to be entitled to participate in the AGM. Such registration must be in effect no later than May 17th, 2017 and should be requested with the nominee well in advance.

Notice of annual general meeting in Hansa Medical AB.pdf

Shareholderproxyform.pdf

The nomination committees explanatory statement to the Annual General Meeting 2017.pdf

Auditors opinion.pdf

Proposed guidelines for Remuneration to Senior Managment.pdf

Remuneration committees evaluation of compensation to Senior Management.pdf

2016-2008

2016

The shareholders of Hansa Medical AB (publ) are summoned to attend the Annual General Meeting (“AGM”) on May 11th, 2016, at 17.00 CET at the auditorium next to the Company’s premises, Scheelevägen 22, Lund, Sweden. Registration starts at 16.30 CET and will be possible until the meeting starts. Refreshments will be served after the meeting.

Right to attend the Annual General Meeting

Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per May 4th, 2016, and who, no later than May 4th, 2016 at 12.00 CET, give notice to the company of their intent to participate at the AGM have a right to participate in the AGM. Notice to participate shall be given in writing to Hansa Medical AB, c/o Fredersen Advokatbyrå AB, Turning Torso, 211 15 Malmö, by e-mail to hansamedical@fredersen.se or by fax to +46-40-232003. The notice shall contain the shareholder’s name, personal identity number or registration number and daytime telephone number and, where applicable, the number of advisors (maximum two). After giving notice of participation the shareholder will receive a confirmation. If no confirmation is received, notice has not been duly given.

A shareholder whose shares are registered under the name of a nominee must temporarily register his/her shares in his/her own name with Euroclear Sweden AB to be entitled to participate in the AGM. Such registration must be in effect no later than May 4th, 2016 and should be requested with the nominee well in advance.

Notice of Annual General Meeting of Hansa Medical AB (publ)

Hansa Medical Annual Report 2015

Shareholder Proxy Form

Remuneration committees evaluation of compensation to senior management

Proposed guidelines for remuneration to senior management

Auditors opinion

2015

2014

2013

2012

2011

2010

2009

2008

Extraordinary General Meeting

2018

The shareholders of Hansa Medical AB (publ) are summoned to attend the Extraordinary General Meeting on 29 October 2018, at 10.00 CET at Hansa Medical’s offices on Scheelevägen 22, Lund, Sweden.

Notice of Extraordinary General Meeting of Hansa Medical AB (publ)

Proxyform.pdf

The shareholders of Hansa Medical AB (publ) are summoned to attend the Extraordinary General Meeting on 11 December 2018, at 10.00 CET at Elite Hotel Ideon, Scheelevägen 72, Lund, Sweden.

Notice of Extraordinary General Meeting of Hansa Medical AB (publ)

Proxyform.pdf

2017

The shareholders of Hansa Medical AB (publ) are summoned to attend the Extraordinary General Meeting on 22 December 2017, at 14:00 am CET at Hansa Medical’s offices on Scheelevägen 22, Lund, Sweden according to the following Notice with attachments:

Notice of Extraordinary General Meeting of Hansa Medical AB (publ)

The board of directors’ of Hansa Medical AB (publ) proposed resolution for approval of the board of directors resolution on a directed issue of ordinary shares

The board of directors’ report in accordance with Chapter 13, Section 6 of the Swedish Companies Act

Proxy form

Incentive Programs

As part of the corporate strategy and in order to retain and incentivize our employees, the following Annual General Meetings resolved to adopt long-term incentive programs.

Long Term Incentive Program 2020

Hansa Biopharma’s Annual General Meeting (the “AGM”) on June 23, 2020 resolved to adopt a long-term incentive program, LTIP2020, based on (a) performance-based share rights and (b) employee stock options.

LTIP2020 based on performance-based share rights

Under the terms of LTIP2020 key employees may participate in the program and may receive so-called performance-based share awards free-of charge (a “Share Right") which, provided certain pre-defined Performance Conditions (as briefly summarized below) and other criteria are met, give the participants the right to acquire ordinary shares in Hansa Biopharma AB at no cost. Each Share Right represents the right to acquire one share and shall carry a vesting period of three years commencing on the day of its allotment to a participant (the “Vesting Period”).

The final number of shares a participant is entitled to receive is, amongst other terms, conditional upon if or to what extend the following performance conditions are met during the vesting Period (the” Performance Conditions”):

  • Condition 1: The U.S. randomised controlled trial is completed during the Vesting Period;
  • Condition 2: Top line data read out of the ongoing phase 2 study in either AMR or GBS is completed during the Vesting Period with data providing a solid scientific rational to continue either of the two programs;
  • Condition 3: At least 70 per cent of the targeted transplantation centers in Europe have been initiated during the Vesting Period;
  • Condition 4: Total shareholder return of at least 25%.

A maximum of 505,096 Share Rights may be allotted to participants under the LTIP 2020 from the day following the 2020 AGM up and until the day prior to the AGM in 2021.

As of December 31, 2020, 389,556 Share Rights have been allotted to plan participants.

LTIP2020 based on stock options

The 2020 AGM also resolved to adopt an employee stock option program under the terms of LTIP2020. Senior executives may participate in the program and receive employee stock options free-of-charge.

The option program 2020 consists of employee stock options allotted free of charge and each employee stock option entitles the holder to subscribe for one new ordinary share in Hansa Biopharma AB. Each employee stock option entitles the holder to receive one new ordinary share in Hansa Biopharma AB at an exercise price of SEK 315.75 corresponding to 125 per cent of the volume weighted average share price during the 10 trading days immediately prior to the offer to subscribe for the employee stock options. The employee stock options have a vesting period of three years, after which the holder is entitled to exercise the options during a period of one month.

A maximum of 506,280 employee stock options may be allotted to participants under the LTIP2020 from the day following the 2020 AGM up and until the day prior to the AGM in 2021. As of December 31, 2020, 477,520 employee stock options have been allotted to the plan participants under the LTIP2020.

Long Term Incentive Program 2019

Hansa Biopharma AB’s Annual General Meeting (the “AGM”) on May 22, 2019 resolved to adopt a long-term incentive program, LTIP 2019. Under the terms of LTIP 2019 key employees may participate in the program and may receive so-called performance-based share awards free-of charge (a “Share Right”) which, provided certain pre-defined Performance Conditions (as briefly summarized below) and other criteria are met, give the participants the right to acquire ordinary shares in Hansa Biopharma AB at no cost. Each Share Right represents the right to acquire one share and shall carry a vesting period of three years commencing on the day of its allotment to a participant (the “Vesting Period”).

The final number of shares a participant is entitled to receive is, amongst other terms, conditional upon meeting the following performance conditions during the Vesting Period (the ”Performance Conditions”):
Condition 1: Obtain market approval in the EU by EMA
Condition 2: Obtain market approval in the United States by the FDA
Condition 3: Total shareholder return (TSR) of at least 25%

A maximum of 550,699 Share Rights may be allotted to participants under the LTIP 2019 from the day following the 2019 AGM up and until the day prior to the AGM in 2020. In order to fund LTIP 2019 (including social security charges), the 2019 AGM further resolved to authorize the Board of Directors to issue a maximum of 715,910 Class C shares which may be converted to ordinary shares whereby the Company’s share capital may not be increased by more than SEK 715,910. The Class C shares were issued and purchased by the Company in September 2019.

As of December 31, 2019 the Company held 1,421,457 of the Class C shares as treasury shares.

Share option program 2019 (SOP 2019)

The 2019 AGM resolved to adopt a share option program, SOP 2019. The SOP 2019 consists of two option series:

Series 1 – Warrants, and Series 2 – Employee stock options.

Series 1 consists of not more than 169,848 warrants that can be transferred to senior executives who are taxable in Sweden. The warrants can be exercised after approximately three years (the “Vesting Period”), after which the holder is entitled to exercise the warrants to subscribe for ordinary shares in the Company during a period of one month. The transfer to participants is made at a price corresponding to the market value of the warrants at the time of transfer. The Company will, pre taxation, subsidy up to 100 per cent of the price for the transfer of the warrants through a one-time subsidy offered to participants.

Series 2 consists of not more than 268,705 employee stock options that can be allotted to senior executives. Each employee stock option entitles the holder to subscribe for one new ordinary share in Hansa Biopharma AB. The options are allotted free of charge. The employee stock options have a vesting period of three years (the “Vesting Period”), after which the holder is entitled to exercise the options during a period of one month.

Each warrant or employee stock option entitles the holder to receive one new ordinary share in Hansa Biopharma AB at a subscription price corresponding to 110 per cent of the volume weighted average share price during the ten (10) trading days immediately prior to the offer to subscribe for the warrants.

In order to fund SOP 2019 (including resulting social security charges), the 2019 AGM further resolved to authorize the Board to issue a maximum of 438,553 ordinary shares, whereby the Company’s share capital may not be increased by more than SEK 438,553. SOP 2019,

Long Term Incentive Program 2018

The Annual General Meeting of Hansa Biopharma (formerly Hansa Medical) held on May 29, 2018 resolved, in accordance with the Board of Directors’ proposal, to adopt a long-term incentive Program for employees of Hansa Biopharma, whereby not more than 52 individuals within the Hansa Biopharma group may participate. The participants in the Program were given the opportunity to acquire warrants at market value and/or receive so called performance based share awards free of charge which, provided that certain conditions are met, may give the right to acquire shares in the Company.

A maximum of 491,419 warrants or 297,902 share awards may be allotted to participants under the Program. The Annual General Meeting further resolved, in accordance with the Board of Directors’ proposal, to adopt certain hedging arrangements to ensure delivery of shares based on share awards to participants at the end of the Program, as well as to cover any social charges arising as a result of the Program. The hedging arrangements include a share issue authorisation for the Board of Directors to issue not more than 391,503 Class C shares, of which 93,601 Class C shares will be issued to cover social security costs, an authorisation for the Board of Directors to repurchase the issued Class C shares and a resolution to transfer the re-purchased shares, after a conversion to ordinary shares, to participants of the Program and in the market in order to cover the cash flow effects of social charges.

Long Term Incentive Program 2016

At the extraordinary general meeting in Hansa Medical, held on 21 November 2016, it was resolved to adopt a long-term incentive program in the form of a performance based share program for employees of the group (”LTIP 2016”). LTIP 2016 has been implemented to motivate and retain competent employees as well as for the alignment of the targets of the employees with those of the shareholders and the company, as well as to increase the motivation of meeting and exceeding the company’s financial targets.

Participants who, with certain exceptions, are employed by Hansa Medical during the entire program period of three years will, by the end of the period, receive so called performance shares, i.e. listed Hansa Medical shares, free of charge, provided that the total shareholder return (the return to shareholders through an increased share price and re investments of any dividends during the vesting period) on the company’s ordinary shares exceeds 25 percent (maximum allotment is obtained if the total shareholder return amounts to 100 percent) during the program period.

As of May 19 2017, 26 employees had chosen to participate in LTIP 2016, meaning that the total number of shares which may be allotted under LTIP 2016 will not exceed 289,750 ordinary shares. Together with a maximum of 96,000 ordinary shares which may be used to secure social charges arising as a result of LTIP 2016, this corresponds to in total 1.1 percent of the existing number of ordinary shares in Hansa Medical. The costs for LTIP 2016 are reported in accordance with IFRS 2. For further details, see the board of directors’ proposal to the general meeting.

Remuneration Policy

Remuneration to Board of Directors

Fees are payable to the Chairman of the Board of Directors and other directors pursuant to a resolution adapted by the annual general meeting.

Directors’ fees were set at the 2020 AGM for a period up to and including the next AGM. The fees for the Board’s work in 2020 were set as follows.

  • SEK 900,000 to the Chairman of the Board of Directors
  • SEK 300,000 to each of the other directors
  • SEK 75,000 is paid to the Chairman and SEK 40,000 is paid to each other board member in the Audit Committee
  • SEK 40,000 is paid to the Chairman and SEK 25,000 is paid to each other board member in the Remuneration Rommittee
  • SEK 25,000 is paid to each board member in the Scientific Committee.

No remuneration other than the abovementioned fees have been paid to the Board except for travel cost reimbursements. The board members are not entitled to any share-based compensation.

Read more

Remuneration to CEO

In 2020, the CEO received a total of SEK 8,854,000 in salaries, bonuses and other benefits.

If notice of termination of employment is made by the Company, the notice period may not exceed six months. Fixed cash salary during the period of notice and any severance pay may together not exceed an amount equivalent to the fixed cash salary for 18 months for the CEO, i.e. 6 plus 12 months. 

The CEO is responsible for his pension provision, thus the Company has no direct pension cost for the CEO.

Read more

Auditors & Their Compensation

KPMG, and Wilkins Kennedy Audit Service are providing audit services on behalf of Hansa Biopharma. The fee for auditing services were SEK 695,000 in 2020. Audit services refer to the legally required examination of the annual report and the book-keeping.

Read more

Board of Directors Policy

The overall task of the board is to manage the affairs of the Company in the best possible manner on behalf of the shareholders. The board must continuously evaluate the Group’s operations, development and financial situation, as well as the operative management.

The board of directors decides upon, among other things: issues concerning the Group’s strategic focus and organization; business plans; financial plans and budget; significant agreements; major investments and commitments; and finance, disclosure, and risk management policies.

The board must also ensure that the Company prepares insider trading policies. The board works according to rules of procedure which are adopted annually and govern the frequency and agenda of board meetings, distribution of materials for meetings, and matters to be presented to the board for information or for a decision. Additionally, the rules of procedure govern how the board work is allocated among the board and its committees. The board has also adopted CEO instructions which govern the allocation of work among the board, the Chairman, and the CEO, and which defines the CEO’s authority.

Pursuant to the Code, the board of directors is to evaluate its work annually, using a systematic and structured process, with the aim of developing the board’s working methods and efficiency.

Evaluation of Board of Directors Work

Pursuant to the Code, the Board is to evaluate its work annually, using a systematic and structured process, with the aim of developing the Board’s working methods and efficiency.

The evaluation has been carried out by the Chairman of the Board by an independent evaluation company, in the end of 2020, interviewing the directors with questions about the work of the Board. The result of the responses has been verbally declared to the directors and the members of the nomination committee.

Management Share Transactions

Transaction Overview